



Department of Health and Human Services
National Institutes of Health

NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

Grant Number: 5U24DK110791-04
FAIN: U24DK110791

Principal Investigator(s):

(b)(6)

Project Title: University of Pittsburgh as the GUDMAP Tissue Hub and Collection Site

(b)(6)

University of Pittsburgh

(b)(6)

Pittsburgh, PA 152132303

Award e-mailed to: ornih@offres.pitt.edu

Period Of Performance:

Budget Period: 06/01/2019 – 05/31/2020

Project Period: 09/15/2016 – 05/31/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$0 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF PITTSBURGH AT PITTSBURGH in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health under Award Number U24DK110791. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

(b)(6)

Grants Management Officer
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

Additional information follows

SECTION I – AWARD DATA – 5U24DK110791-04**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$39,353
Fringe Benefits	\$12,354
Personnel Costs (Subtotal)	\$51,707
Materials & Supplies	\$4,497
Travel	\$1,697
Other	\$7,528

Federal Direct Costs	\$65,429
Federal F&A Costs	\$34,571
Approved Budget	\$100,000
Total Amount of Federal Funds Obligated (Federal Share)	\$100,000
Less Unobligated Balance	\$100,000
TOTAL FEDERAL AWARD AMOUNT	\$0

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$0

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
4	\$0	\$0
5	\$613,000	\$613,000

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Diabetes, Digestive, and Kidney Diseases Extramural Research
CFDA Number: 93.847
EIN: 1250965591A1
Document Number: UDK110791A
PMS Account Type: P (Subaccount)
Fiscal Year: 2019

IC	CAN	2019	2020
DK	8472288	\$0	\$613,000

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: KDH KDB / **OC:** 414P / **Released:** (b)(6) 06/04/2019
Award Processed: 06/05/2019 12:08:14 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U24DK110791-04

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5U24DK110791-04

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget

- period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) U24DK110791. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Other Research (Add/Deduct Option)

SECTION IV – DK Special Terms and Conditions – 5U24DK110791-04

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

RESTRICTION: Funds may only be used to pay for the cost of processing, shipping and handling tissue samples from external sources to the GUDMAP atlas projects.

Notice: Under governing regulations, Federal funds administered by the Department of Health and Human Services shall not be expended for research involving human subjects, and individuals shall not be enrolled in such research, without prior approval by the Office of Human Research Protections (OHRP) of an assurance to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction applies to all collaborating sites without OHRP-approved assurances, whether domestic or foreign, and compliance must be ensured by the awardee.

Notice: Under governing policy, federal funds administered by the Public Health Service (PHS) shall not be expended for research involving live vertebrate animals without prior approval by the Office of Laboratory Animal Welfare (OLAW) of an assurance to comply with the PHS policy on humane care and use of laboratory animals. This restriction applies to all performance sites (e.g., collaborating institutions, subcontractors, subgrantees) without OLAW-approved assurances, whether domestic or foreign.

The issuance of this award has been delayed due to administrative funding considerations. According to NIH policy, if pre-award costs are necessary, they may be approved by the authorized Institution Official(s).

This award uses as an offset the unobligated balance (\$100,000) from the -02 year Federal Financial Report.

In addition to the PI, the following individuals are named as key personnel:

(b)(6)

Written prior approval is required if any of the individual(s) named above withdraws from the project entirely, is absent from the project during any continuous period of 3 months or more, or reduces time devoted to the project by 25 percent or more from the level that was approved at the time of award.

This grant is in response to RFA/PA [DK15-016](#). Acceptance of this award requires compliance with this solicitation. See the NIH Guide at <http://grants.nih.gov/grants/guide/index.html> for copy of the RFA/PA that includes administrative and programmatic requirements specific to this award.

In accordance with the Salary Limitation in NIH Guide Notice [NOT-OD-19-031](#), Notice of Fiscal Policies in Effect for FY2019, none of the funds in this award shall be used to pay the salary of an individual at a rate in excess of Executive Level II. Therefore, this award and/or future years are adjusted accordingly, if applicable. See the [Salary Cap Summary](#) for a historical record of the salary cap, including effective dates.

Grantees can determine which progress reports are due through the website located at <https://public.era.nih.gov/chl/public/search/index.jsp> and should periodically check the site, which is updated on or around the 30th of each month. Progress report due dates are also available in the eRA Commons Status system. In addition, automatic e-mail notifications are sent to the PD/PI prior to due date.

As of October 17, 2014, the National Institutes of Health (NIH) requires grantees to submit all type 5 progress reports using the eRA Research Performance Progress Report (RPPR) module. Annual progress reports submitted in any format other than the RPPR will not be processed by the NIH and will require resubmission through the RPPR module in accordance with NIH Guide Notice [NOT-OD-15-014](#) released October 16, 2014.

